Edition:
United Kingdom

Dr.Reddy's Laboratories Ltd (REDY.BO)

REDY.BO on Bombay Stock Exchange

2,089.15INR
11:25am BST
Change (% chg)

Rs-228.30 (-9.85%)
Prev Close
Rs2,317.45
Open
Rs2,239.40
Day's High
Rs2,239.40
Day's Low
Rs2,071.50
Volume
323,759
Avg. Vol
99,198
52-wk High
Rs2,788.00
52-wk Low
Rs1,888.00

Chart for

About

Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and... (more)

Overall

Beta: 0.11
Market Cap(Mil.): Rs394,104.81
Shares Outstanding(Mil.): 165.88
Dividend: 20.00
Yield (%): 0.84

Financials

  REDY.BO Industry Sector
P/E (TTM): 32.79 30.93 32.76
EPS (TTM): 72.46 -- --
ROI: -- 15.07 14.61
ROE: -- 16.60 16.34

Indivior's shares jump 30 pct after U.S. court blocks sale of rival generic

July 16 Indivior Plc's shares soared as much as 30 percent on Monday after a U.S. court blocked India's Dr.Reddy's Laboratories from selling copycat versions of the British drugmaker's bestselling opioid addiction treatment in the United States.

8:16am BST

Indivior says 2018 profit to fall short after U.S. market hit

British drugmaker Indivior said on Wednesday its 2018 revenue and adjusted net income would come in below its previous forecast, hurt by the launch of generic versions of its bestselling opioid addiction treatment in the United States.

11 Jul 2018

Indivior warning on anti-opioid drug competition sends shares tumbling

British drugmaker Indivior warned on Wednesday it would miss its full-year profit target as its best-selling opioid addiction drug faces new competitors in the United States, sending its shares down 37 percent.

11 Jul 2018

UPDATE 2-Indivior warning on anti-opioid drug competition sends shares tumbling

* Best-seller's rapid market share loss to hit revenue by $25 mln

11 Jul 2018

Indivior gets breather after court extends order blocking generic rival

Indivior Plc got a breather on Friday as a U.S. court extended a restraining order blocking a rival from launching a generic version of its bestselling opioid addiction treatment in the United States.

29 Jun 2018

UPDATE 2-Indivior gets breather after court extends order blocking generic rival

* Update on Sublocade will be key to sentiment-Jefferies (Adds share move, analyst comments)

29 Jun 2018

U.S. court extends Indivior's restraining order against Dr. Reddy's generic drug

June 29 British drugmaker Indivior Plc said on Friday a U.S. court extended the restraining order blocking Indian pharmaceutical firm Dr.Reddy's Laboratories from launching a generic version of its bestselling opioid addiction treatment in the United States.

29 Jun 2018

Indivior shares rise after U.S. court order blocks generic rival drug

Shares in drugmaker Indivior rose on Monday after a U.S. Court granted a temporary restraining order blocking Dr. Reddy's Laboratories from launching a generic version of Indivior's best-selling opioid addiction treatment.

18 Jun 2018

Indian shares post fourth straight weekly gain; Infosys, TCS boost

* NSE index ended 0.09 pct higher, BSE index closed up 0.06 pct

15 Jun 2018

Indian shares close slightly higher; SBI, Dr.Reddy's gain on Q4 results

May 22 Indian shares ended slightly higher on Tuesday, driven by gains in Dr. Reddy's Laboratories Ltd and State Bank of India (SBI) following their quarterly results.

22 May 2018

Earnings vs. Estimates